Inquire Before Buying - EMEA Liquid Biopsy Market Size, Scope and Growth Analysis By 2028

EMEA Liquid Biopsy Market Research Report: Forecast (2023-2028)

By Product and Services (Equipment, Assay Kits, Services), By Circulating Biomarker (Circulating Tumour Cell (CTC), Circulating Tumour DNA (ctDNA), Cell Free DNA (cfDNA), Extracell......ular Vesicle (EVS)), By Technology (Multi gene analysis by Next Generation Sequencing (NGS), Single gene analysis by Polymer chase reaction (PCR)), By Sample Type (Blood Urine Others (Cerebrospinal Fluid, Plasma, Saliva, etc.)), By Application (By Cancer Application, By Non Cancer Application, By Clinical Application), By End User (Hospital and Physician laboratories, Reference Laboratories, Academic & Research Centre), By Country (Germany, The UK, France, Italy, Spain, Saudi Arabia, The UAE, Egypt, South Africa, Rest of Europe Middle East & Africa) By Company (Thermofisher Scientific, Hoffmann-La Roche Ltd, Sysmex Corporation, Qiagen N.V., Guardant Health, Bio Rad, Neo Genomics, Epigenomics, Menarini-Silicon Biosystems, Agena Bioscience Inc., Silicon Biosystems, Pathway Genomics Corporation, Illumina Inc., Myraid Genetics., and others) Read more

Healthcare
Jul 2023
Pages 178
Report Format: PDF, Excel, PPT

Market Definition

Liquid Biopsy is a convenient, fast, and non-invasive sampling technique that can show the changes in tumour gene profile & provide a robust base for individual therapy & early diagnosis of cancer. The demand for liquid biopsy is arising significantly for the detection & isolation of circulating tumour DNA, RNA, and exosomes to diagnose the recurrence of cancerous cells in the treatment process.

Market Insights & Analysis: EMEA Liquid Biopsy Market (2023-28):

The EMEA Liquid Biopsy Market is projected to grow at a CAGR of around 13.98% during the forecast period, 2023-28. The market noticed consistent growth since the past few years, owing to the increasing prevalence of cancer patients coupled with a surge in demand for minimally invasive & fast diagnostic tests for detection. The rising prevalence of cancer has affected patients in the EMEA region, owing to the sedentary lifestyle, harmful carcinogenic elements in the environment, etc. According to the World Health Organisation (WHO), there were around 4 million cancer cases in Europe in 2020, of which nearly 2.4 million cases were in men & over 2.1 million in women.

Report Coverage	Details
Study Period	Historical Data: 2018-21
	Base Year: 2022
	Forecast Period: 2023-28
CAGR (2023-2028)	13.98%
Country Covered	Germany, The UK, France, Italy, Spain, Saudi Arabia, The UAE, Egypt, South Africa, Rest of Europe Middle East & Africa
Key Companies Profiled	Thermofisher Scientific, Hoffmann-La Roche Ltd, Sysmex Corporation, Qiagen N.V., Guardant Health, Bio Rad, Neo Genomics, Epigenomics, Menarini-Silicon Biosystems, Agena Bioscience Inc., Silicon Biosystems, Pathway Genomics Corporation, Illumina Inc., Myraid Genetics., Others
Unit Denominations	USD Million/Billion

Moving forward, it is presumed that these cases would elevate in the coming years. Hence, this has affected the consciousness of the population & due to this individual are becoming more aware of early diagnosis & the treatment of the diseases. In response to this demand, various healthcare institutions are developing liquid biopsy test procedures for the early detection of cancer among patients. For instance, in 2023, Vall d’Hebron Institute of Oncology (VHIO) in Barcelona integrated Liquid Biopsy Testing for cancer patients to help healthcare professionals make more informed treatment decisions. These developments are supplementing the demand for liquid biopsy & have the potential to accelerate the EMEA Liquid Biopsy Market growth in the forecast year as well.nderstanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.

EMEA Liquid Biopsy Market Research Report (2023-2028) - Table of Contents

Market Segmentation
Introduction
1. Product Definition
2. Research Process
3. Assumptions
Executive Summary
Impact of COVID-19 on Europe Middle East & Africa (EMEA) Liquid Biopsy Market
Europe Middle East & Africa (EMEA) Liquid Biopsy Trends & Insights
Europe Middle East & Africa (EMEA) Liquid Biopsy Dynamics
1. Drivers
2. Challenges
Europe Middle East & Africa (EMEA) Liquid Biopsy Policy & Regulations
Europe Middle East & Africa (EMEA) Liquid Biopsy Market Porters Five Forces Analysis
Europe Middle East & Africa (EMEA) Liquid Biopsy Market Patent Analysis
Europe Middle East & Africa (EMEA) Liquid Biopsy Growth Opportunities & Hotspots
Europe Middle East & Africa (EMEA) Liquid Biopsy Analysis, 2018-2028F
1. Market Size & Outlook
  1. Revenues (USD Million)
2. Market Share & Outlook
  1. By Product and Services
    1. Equipment
    2. Assay Kits
    3. Services
  2. By Circulating Biomarker
    1. Circulating Tumour Cell (CTC)
    2. Circulating Tumour DNA (ctDNA)
    3. Cell Free DNA (cfDNA)
    4. Extracellular Vesicle (EVS)
  3. By Technology
    1. Multi gene analysis by Next Generation Sequencing (NGS)
    2. Single gene analysis by Polymer chase reaction (PCR)
  4. By Sample Type
    1. Blood
    2. Urine
    3. Others (Cerebrospinal Fluid, Plasma, Saliva, etc.)
  5. By Application
    1. By Cancer Application
      1. Lung Cancer
      2. Breast Cancer
      3. Colorectal Cancer
      4. Prostate Cancer
      5. Melanoma cancer
      6. Others (Pancreatic, Liver, etc.)
    2. By Non Cancer Application
      1. Non Invasive Parental Testing
      2. Organ Transplantation
      3. Infectious Diseases
    3. By Clinical Application
      1. Early Cancer Screening
      2. Therapy Selection
      3. Treatment Monitoring
      4. Recurrence Monitoring
  6. By End User
    1. Hospital and Physician laboratories
    2. Reference Laboratories
    3. Academic & Research Centre
  7. By Country
    1. Germany
    2. The UK
    3. France
    4. Italy
    5. Spain
    6. Saudi Arabia
    7. The UAE
    8. Egypt
    9. South Africa
    10. Rest of Europe Middle East & Africa
  8. By Company
    1. Market Share
    2. Competition Characteristics
Germany Liquid Biopsy Market Analysis, 2018-2028F
1. Market Size & Outlook
  1. Revenues (USD Million)
2. Market Share & Outlook
  1. By Product & Service
  2. By Circulating Marker
  3. By Sample
  4. By End User
The UK Liquid Biopsy Market Analysis, 2018-2028F
1. Market Size & Outlook
  1. Revenues (USD Million)
2. Market Share & Outlook
  1. By Product & Service
  2. By Circulating Marker
  3. By Sample
  4. By End User
France Liquid Biopsy Market Analysis, 2018-2028F
1. Market Size & Outlook
  1. Revenues (USD Million)
2. Market Share & Outlook
  1. By Product & Service
  2. By Circulating Marker
  3. By Sample
  4. By End User
Italy Liquid Biopsy Market Analysis, 2018-2028F
1. Market Size & Outlook
  1. Revenues (USD Million)
2. Market Share & Outlook
  1. By Product & Service
  2. By Circulating Marker
  3. By Sample
  4. By End User
Spain Liquid Biopsy Market Analysis, 2018-2028F
1. Market Size & Outlook
  1. Revenues (USD Million)
2. Market Share & Outlook
  1. By Product & Service
  2. By Circulating Marker
  3. By Sample
  4. By End User
Saudi Arabia Liquid Biopsy Market Analysis, 2018-2028F
1. Market Size & Outlook
  1. Revenues (USD Million)
2. Market Share & Outlook
  1. By Product & Service
  2. By Circulating Marker
  3. By Sample
  4. By End User
The UAE Liquid Biopsy Market Analysis, 2018-2028F
1. Market Size & Outlook
  1. Revenues (USD Million)
2. Market Share & Outlook
  1. By Product & Service
  2. By Circulating Marker
  3. By Sample
  4. By End User
Egypt Liquid Biopsy Market Analysis, 2018-2028F
1. Market Size & Outlook
  1. Revenues (USD Million)
2. Market Share & Outlook
  1. By Product & Service
  2. By Circulating Marker
  3. By Sample
  4. By End User
South Africa Liquid Biopsy Market Analysis, 2018-2028F
1. Market Size & Outlook
  1. Revenues (USD Million)
2. Market Share & Outlook
  1. By Product & Service
  2. By Circulating Marker
  3. By Sample
  4. By End User
Europe Middle East & Africa (EMEA) Liquid Biopsy Market Key Strategic Imperatives for Success & Growth
Competitive Benchmarking
1. Competition Matrix
  1. Product Portfolio
  2. Target Markets
  3. Target End Users
  4. Research & Development
  5. Strategic Alliances
  6. Strategic Initiatives
2. Company Profiles (Business Description, Product Offering, Strategic Alliances or Partnerships, etc.)
  1. Thermofisher Scientific
  2. Hoffmann-La Roche Ltd
  3. Sysmex Corporation
  4. Qiagen N.V.
  5. Guardant Health
  6. Bio Rad
  7. Neo Genomics
  8. Epigenomics
  9. Menarini-Silicon Biosystems
  10. Agena Bioscience Inc.
  11. Silicon Biosystems
  12. Pathway Genomics Corporation
  13. Others (Myraid Genetics, Illumina Inc.,etc)
Disclaimer

MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:

1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.

2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.

3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.

4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making

FILL THE FORM TO INQUIRE BEFORE BUYING THIS REPORT

Name *

Email ID *

Country *

Contact Number *

Your Enquiry Details

Your data is 100% confidential & secure

By submitting, you agree to our Terms and Privacy Policy .

Flexible Licensing Options

We offer flexible licensing options to cater to varying organizational needs. Choose the pricing pack that best suits your requirements:

Buy Now

Related Reports

Talk to our Consultant

Customization Offered

Request Customization